Michael J. Fox Foundation Collaborates with Biognosys on Parkinson's Biomarker Project
The Michael J. Fox Foundation for Parkinson's Research (MJFF) has partnered with Swiss biotech company Biognosys to focus on the biomarker LRRK2, which is a significant target in Parkinson's disease drug discovery. This collaboration aims to develop quantitative biomarker assays that could guide therapy development and identify patients suitable for LRRK2-directed treatments. LRRK2 has become a compelling target due to its excessive activity in Parkinson's disease, but the lack of assays has hindered progress. Denali Therapeutics' DNL151, a small-molecule LRRK2 inhibitor, is currently in phase 2b clinical trials, with results expected later this year. Other companies like Neuron23, Oncodesign Precision Medicines, and Brenig Therapeutics are also developing LRRK2-targeted therapies. 
